OrbiMed

Congratulations to our portfolio company Caris Life Sciences on its FDA approval of MI Cancer Seek™️!

Congratulations to our team and our portfolio company Aliada Therapeutics! AbbVie is set to acquire Aliada for $1.4B in an all-cash transaction. This move brings Aliada's innovative blood-brain barrier technology and promising Alzheimer's therapy into AbbVie's pipeline. Read more here: https://lnkd.in/eNuZjxrQ

Congrats to our portfolio company Upstream Bio for having an upsized IPO at $17 per share, raising $255M! The clinical-stage biotech company focusing on inflammatory diseases, with an initial focus on respiratory diseases, will show *up* on Nasdaq under $UPB. 

OrbiMed has entered into a $50M non-dilutive financing agreement with POXEL, monetizing future royalties from the sales of TWYMEEG®, Poxel’s first-in-class product marketed for treating type 2 diabetes, in Japan. https://lnkd.in/e54jGJti

Congrats to our portfolio company, BioAge Labs, on its upsized IPO! Thanks to the hard work of both of our teams, the IPO priced at $18 per share, raising $198M. Find the clinical-stage company harnessing the power of anti-aging biology for metabolic diseases on Nasdaq under $BIOA. https://lnkd.in/ejgrzdKT

Congrats to our team and our portfolio company MBX Biosciences, Inc. on its IPO! MBX priced the $163.2M IPO at $16 per share. The endocrine and metabolic clinical-stage company can be found on Nasdaq under ticker $MBX. https://lnkd.in/eaUfY5CZ

Thank you Kyle LaHucik, at Endpoints News, for covering the launch of Belenos Biosciences, our new biotech startup in partnership with KeyMed Biosciences. Belenos is led by CEO Donnie McGrath, an OrbiMed Venture Partner & former BioShin CEO. https://lnkd.in/ec_4Gi-U

We are excited to publicly announce the launch of Exsilio Therapeutics, a biotech developing redosable genomic medicines for a broad range of diseases. Exsilio means leap (Latin), and this leap in genomic medicine would not be possible without the work of Roy Amariglio, the principal on our private equity team who founded the company. Together with Tal Zaks, a partner on our private equity team who joined as Chairman and CEO, and with the funding of several other investors, Exsilio is now well positioned to advance its genomic medicines. https://lnkd.in/eGKG8re4

Tomorrow, Tal Zaks, an OrbiMed Partner & former Chief Medical Officer of Moderna, will share his thoughts with The National Academies of Sciences, Engineering, and Medicine. Based on his experience as a drug developer and investor, Tal will share his insights on what it takes to better align investments in innovation with addressing unmet needs and improving health outcomes. Tune in on Tuesday, June 18th at 11:00 am ET here: https://lnkd.in/ehJfzQm3

Congratulations to our portfolio company PROTEOLOGIX Inc on entering a definitive agreement to be acquired by Johnson & Johnson for $850 million upfront plus a potential milestone payment! OrbiMed co-incubated PROTEOLOGIX Inc in 2021 and was one of the company’s largest investors. PROTEOLOGIX Inc is focused on developing bispecific antibodies for immune-mediated diseases, with lead programs targeting significant unmet medical needs in atopic dermatitis (eczema) and other indications. Read more here: https://lnkd.in/eUa9HSCV